Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
'As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments, to bring these new innovations to patients,' said Hubertus von Baumbach, Chairman of the Board of Managing Directors. 'It is important that we use every opportunity to bring these new treatments to patients as fast as possible – this is our number one priority.' Strong Growth in IMETA
In India, Middle East, Turkey, and Africa (IMETA) region, the company recorded net sales of 855 million EUR (2023: 732 million EUR), a 17% increase compared to the previous year.
Derek O'Leary, Regional Managing Director at Boehringer Ingelheim India, Middle East, Turkey and Africa (IMETA) said: 'Our strong performance in 2024 underscores our commitment to addressing unmet medical needs in both human and animal health. We will continue to work towards expanding access to innovative treatments for people and strengthen our efforts to safeguard animal health and well-being, impacting a greater number of lives. In partnerhip with our stakeholders, we are eager to build on this momentum in 2025 through further science-backed innovations tailored to the needs of both patients and animals.' Human Pharma: investing in existing products and new launches
Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by the treatment of chronic kidney diseases, type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. Treatments used for idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion.
The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit's net sales.
'If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,' said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. 'With the innovations currently in our pipeline we will further increase investments in R&D in the years to come.'
After positive data from pivotal studies, the company is preparing multiple new product launches to advance care for patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis as well as the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients.
Both treatments have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval. Animal Health: rapid response against transboundary animal diseases
Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion.
Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases (TADs), such as avian influenza, bluetongue virus and foot-and-mouth disease. These diseases pose a significant risk to animal health, impede global trade, and constrain food supply. Sustainable Development
Boehringer Ingelheim is on track in its target to become carbon neutral in its company operations by 2030. It increased global renewable electricity purchases to around 75% in 2024, primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable energy generation to 95% of its energy needs.
As part of its global effort to stop rabies, the company provided 46 million rabies vaccine doses and supported vaccination campaigns in endemic countries. The 'Angels' initiative, which aims to optimize the quality of treatment in existing stroke centers, added over 1,000 organizations to the network. It is the largest stroke community in the world, now encompassing 237,000 healthcare professionals from more than 9,000 hospitals in 158 countries and has helped 19 million stroke patients to date. Outlook
The general trends and developments of the past year are expected to continue to impact 2025. The company expects a continued rise in the number of patients reached, and a slight year-on-year increase in net sales, adjusted for currency and extraordinary effects.
* sales growth numbers are adjusted for currency effects
**one-sided p-value from a z-test of the null hypothesis ORR ?30%
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Boehringer Ingelheim – Life Forward | Boehringer Ingelheim.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
2 days ago
- Arabian Post
China Development Bank Expands Funding with Dual‑Currency Bond Listing
China Development Bank has successfully listed two bonds on Nasdaq Dubai, raising a total of more than US $1 billion in a strategic bid to broaden its foreign‑currency funding channels and attract global investors. The issuance includes a US $500 million three‑year floating‑rate tranche tied to SOFR + 30 bps, and a €500 million three‑year fixed‑rate tranche offering a 2.25 percent coupon. Both tranches carry an A1 rating from Moody's. Investor appetite proved robust across both offerings. The euro tranche was subscribed 15 times over, marking the highest subscription ratio so far for a Chinese bank's single public bond issue, while demand for the US dollar tranche was three times oversubscribed, achieving the tightest spread to SOFR among comparable issuances. Interest originated primarily from institutions in Europe, the Middle East and Asia, including banks, sovereign entities, investment funds and asset managers; more than 30 percent of the euro tranche was allocated to high‑quality supranational, sovereign, and agency investors. Nasdaq Dubai welcomed the listing under the official securities list of the Dubai Financial Services Authority, with Hamed Ali, CEO of both Nasdaq Dubai and Dubai Financial Market, describing the move as a deepening of financial ties with Chinese lenders. 'This milestone underscores Dubai's position as a trusted global hub for cross‑border capital flows,' he commented. ADVERTISEMENT This dual‑currency offering forms part of CDB's long‑term strategy to diversify its funding base. Since resuming international bond issuances in 2015, the lender has raised the equivalent of US $42.5 billion in multiple currencies—USD, EUR, GBP and HKD—through public and private offerings. Nasdaq Dubai, which already hosts over US $13.4 billion in listed Chinese fixed‑income securities and more than US $136.2 billion in total debt issuances, has positioned itself as a preferred centre for Chinese and international issuers seeking cross‑border access. The structure of the issuance—offering both floating‑rate and fixed‑rate components in parallel—addresses differing investor needs. The floating‑rate instrument appeals to US dollar investors aiming to hedge against interest rate uncertainty by aligning returns with short‑term rates, while the fixed‑rate euro tranche delivers stable yield expectations at a time when eurozone rates remain relatively low. The A1 credit rating lends further reassurance of CDB's high repayment capacity. Market analysts suggest that the record subscription levels reflect strong global confidence in sovereign or quasi‑sovereign credit combined with growing investor demand for diversified, high‑quality issuances from non‑Western borrowers. One commentator told Bloomberg that the euro tranche 'demonstrated unprecedented demand for Chinese credit offshore,' a sentiment echoed by allocations to Europe‑based sovereign wealth and supranational issuers. Nasdaq Dubai's hosting of the bond listing lifts its international profile. The exchange has actively courted Chinese sovereign and financial institution issuers—including ICBC, Bank of China, China Construction Bank, China's ministry of finance, and Hong Kong Government entities—by facilitating access to capital from Europe, the Gulf and Asia. With total listings now exceeding US $13.4 billion, the venue's debt market is fast approaching the scale of some European sub‑exchanges. Financial practitioners suggest the listing may act as a template for future issuances from Chinese state‑owned financial institutions, offering investor diversification benefits and potential cost savings through a more competitive pricing environment. European investors, in particular, appear drawn to the euro tranche's high demand, which points to appetite for enhanced yield coupled with capital security. Experts in Gulf and Asia‑Pacific fund flows are now closely watching whether more Chinese issuers will harness Nasdaq Dubai's platform for offshore funding, thereby recalibrating traditional bond‑raising channels via London or New York. Dubai's regulatory framework, overseen by the DFSA, alongside its strategic position between Europe and Asia, provides a compelling value proposition. The success of CDB's dual tranches also underscores the evolving depth of global bond markets. The presence of SOFR‑linked floating‑rate bonds shows growing acceptance of this benchmark outside North America. Meanwhile, the euro tranche sets a new benchmark for Chinese issuers in terms of subscription records and tranche structuring. For China Development Bank, this launch enhances its capabilities to fund infrastructure, social development and global lending priorities. For Nasdaq Dubai, it represents another step forward in building a globally integrated bond market serving issuers and investors across major time zones.
Hi Dubai
10-07-2025
- Hi Dubai
China Development Bank Lists Dual-Currency Bonds on Nasdaq Dubai in Record-Setting Issuance
China Development Bank (CDB) has listed dual-currency bonds worth USD 1 billion on Nasdaq Dubai, marking a significant milestone in cross-border finance and reinforcing Dubai's role as a global hub for fixed income investment. The landmark issuance includes a USD 500 million three-year floating-rate bond and a EUR 500 million three-year fixed-rate bond. Both tranches, rated A1 by Moody's, attracted overwhelming investor demand—underscoring strong global appetite for Chinese credit and confidence in Dubai's market infrastructure. The euro tranche saw record demand, oversubscribed 15 times—setting a new high for a Chinese bank's public bond issuance. The US dollar tranche was oversubscribed three times, achieving the tightest spread to SOFR among similar issuances from Chinese institutions. Investors spanned across Europe, the Middle East, and Asia, with participation from sovereign entities, asset managers, and global banks. Notably, over 30% of euro tranche allocations went to top-tier Supranational, Sovereign, and Agency (SSA) investors. Hamed Ali, CEO of Nasdaq Dubai and DFM, said the listing further deepens ties with Chinese financial institutions and reaffirms Dubai's standing as a reliable platform for cross-border capital flows. CDB's dual-currency offering aligns with its broader strategy to diversify funding and grow its international investor base. Since 2015, the bank has raised USD 42.5 billion through offshore issuances in multiple currencies. Nasdaq Dubai now hosts over USD 13.4 billion in Chinese fixed income listings and more than USD 136.2 billion in total debt issuances. News Source: Emirates News Agency
Al Etihad
09-07-2025
- Al Etihad
Nasdaq Dubai welcomes China Development Bank's Dual-Currency Bond Listing
9 July 2025 14:50 DUBAI (ALETIHAD)Nasdaq Dubai welcomed the landmark listing of dual-currency bonds issued by China Development Bank (CDB), reinforcing Dubai's status as a strategic international hub for fixed income issuances and cross-border bonds, admitted to Nasdaq Dubai's market and listed on the official securities list maintained by the Dubai Financial Services Authority (DFSA), include a USD 500 million three-year floating-rate tranche priced at SOFR +30 basis points and a EUR 500 million three-year fixed-rate tranche with a coupon of 2.25%. Both tranches have received an A1 rating from Moody's, indicating strong credit issuance attracted significant investor interest, particularly in Europe, the Middle East, and Asia. The euro-denominated tranche was oversubscribed 15 times, the highest subscription level ever achieved by a Chinese bank in a single public bond issuance. The US dollar tranche was oversubscribed three times, setting a record for the tightest spread to SOFR among comparable Chinese bank included banks, sovereign entities, funds, and asset managers from key financial centres such as Switzerland, Germany, the UK, Spain, the Middle East, and Supranational, Sovereign, and Agency (SSA) investors accounted for over 30% of the euro tranche of Nasdaq Dubai and Dubai Financial Market (DFM), Hamed Ali, said, 'We are pleased to welcome China Development Bank's landmark dual-currency bond listing to Nasdaq Dubai, further strengthening our deepening ties with China's leading financial institutions. This milestone underscores Dubai's position as a trusted global hub for cross-border capital flows and highlights the confidence international investors place in Dubai's market infrastructure.'The dual-currency issuance is part of CDB's strategy to diversify its foreign-currency funding and expand its international investor base. Since resuming offshore bond issuances in 2015, CDB has raised the equivalent of $42.5 billion in multiple currencies, including USD, EUR, GBP, and HKD, through public and private Dubai is continuing to expand its presence as a preferred venue for Chinese issuers. Currently, the exchange hosts over $13.4 billion in Chinese fixed-income listings from institutions including ICBC, Bank of China, China Construction Bank, China's Ministry of Finance and the Hong Kong Government. Total debt issuances listed on Nasdaq Dubai now exceed $136.2 billion.
